VRNA Company Profile and Key Details
Verona Pharma plc
VRNA Stock Price Chart
Stock Price Today
Verona Pharma plc (VRNA) stock surged +2.84%, trading at $55.02 on NASDAQ, up from the previous close of $53.50. The stock opened at $54.33, fluctuating between $52.60 and $55.19 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Company Information
| Employees | 79 |
| Beta | 0.42 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Verona Pharma plc (NASDAQ: VRNA) stock price is $55.02 in the last trading session. During the trading session, VRNA stock reached the peak price of $55.19 while $52.60 was the lowest point it dropped to. The percentage change in VRNA stock occurred in the recent session was 2.84% while the dollar amount for the price change in VRNA stock was $1.52.
The NASDAQ listed VRNA is part of Biotechnology industry that operates in the broader Healthcare sector. Verona Pharma plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Ostra Jewell
Senior Vice President of HR
Dr. Kathleen A. Rickard
Chief Medical Officer
Dr. David S. Zaccardelli
Pres, Chief Executive Officer & Executive Director
Dr. Tara Rheault M.P.H., Ph.D.
Senior Vice President of R&D
Dr. Peter Spargo
Senior Vice President of Chemistry Manufacturing & Controls
Ms. Nina Church
Executive Director of Global Clinical Devel.
Ms. Victoria Stewart
Director of Communications
Mr. Matthew Casbon
Vice President of Sales, Marketing & Training
Mr. Mark W. Hahn
Chief Financial Officer
Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA
Gen. Counsel
VRNA's closing price is 369.71% higher than its 52-week low of $11.39 where as its distance from 52-week high of $55.42 is -3.47%.
Number of VRNA employees currently stands at 79.
Official Website of VRNA is: https://www.veronapharma.com
VRNA could be contacted at phone 442 032 834200 and can also be accessed through its website. VRNA operates from 3 More London Riverside, London, SE1 2RE, United Kingdom.
VRNA stock volume for the day was 615.6K shares. The average number of VRNA shares traded daily for last 3 months was 1.17M.
The market value of VRNA currently stands at $4.50B with its latest stock price at $55.02 and 81.83M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com